Oftedal L, Maple-Grodem J, Dalen I, Tysnes OB, Pedersen KF, Alves G, Lange J. Association of CSF glucocerebrosidase activity with the risk of incident dementia in patients with Parkinson Disease. Neurology. 2023;100:e388–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Franchi PM, Kulagina N, Ilinskaya A, Hoffpauir B, Qian MG, Sugimoto H. Multifaceted approach for quantification and enzymatic activity of Iduronate-2-Sulfatase to support developing gene therapy for Hunter Syndrome. AAPS J. 2023;25:61.

Article  CAS  PubMed  Google Scholar 

European Medicines Agency. Hemgenix. 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/hemgenix. Accessed 31 Dec 2023.

U.S. Food and Drug Administration. Human gene therapy for hemophilia: Guidance for industry. 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-hemophilia. Accessed 31 Dec 2023.

Felbor U, Kessler B, Mothes W, Goebel HH, Ploegh HL, et al. Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc Natl Acad Sci U S A. 2002;99:7883–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brix K. Lysosomal proteases. In: Saftig P, editor. Lysosomes. Boston, MA: Springer, US; 2005. p. 50–9.

Chapter  Google Scholar 

Garmo C, Bajwa T, Burns B. Physiology, Clotting Mechanism. Treasure Island: StatPearls; 2023.

Google Scholar 

Palta S, Saroa R, Palta A. Overview of the coagulation system. Indian J Anaesth. 2014;58:515–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patricia JJ, Dhamoon AS. Physiology, Digestion. Treasure Island: StatPearls; 2023.

Google Scholar 

Beck DB, Aksentijevich I. Biochemistry of autoinflammatory diseases: Catalyzing monogenic disease. Front Immunol. 2019;10:101.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonam SR, Wang F, Muller S. Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019;18:923–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kitcharoensakkul M, Cooper MA. Rheumatologic and autoimmune manifestations in primary immune deficiency. Curr Opin Allergy Clin Immunol. 2019;19:545–52.

Article  CAS  PubMed  Google Scholar 

Robak LA, Jansen IE, van Rooij J, Uitterlinden AG, Kraaij R, Jankovic J, et al. Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease. Brain. 2017;140:3191–203.

Article  PubMed  PubMed Central  Google Scholar 

Sauer AV, Brigida I, Carriglio N, Aiuti A. Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency. Front Immunol. 2012;3:265.

Article  PubMed  PubMed Central  Google Scholar 

Sreedhar A, Zhao Y. Dysregulated metabolic enzymes and metabolic reprogramming in cancer cells. Biomed Rep. 2018;8:3–10.

CAS  PubMed  Google Scholar 

Ferreira CR, Rahman S, Keller M, Zschocke J, Group IA. An international classification of inherited metabolic disorders (ICIMD). J Inherit Metab Dis. 2021;44:164-77. https://doi.org/10.1002/jimd.12348.

Platt FM, d’Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers. 2018;4:27.

Article  PubMed  Google Scholar 

Ferreira CR, van Karnebeek CDM. Inborn errors of metabolism. Handb Clin Neurol. 2019;162:449–81.

Article  PubMed  Google Scholar 

Boyer SW, Barclay LJ, Burrage LC. Inherited metabolic disorders: Aspects of chronic nutrition management. Nutr Clin Pract. 2015;30:502–10.

Article  PubMed  PubMed Central  Google Scholar 

Rha AK, Maguire AS, Martin DR. GM1 gangliosidosis: Mechanisms and management. Appl Clin Genet. 2021;14:209–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Platt FM. Emptying the stores: lysosomal diseases and therapeutic strategies. Nat Rev Drug Discov. 2018;17:133–50.

Article  CAS  PubMed  Google Scholar 

Ellison S, Parker H, Bigger B. Advances in therapies for neurological lysosomal storage disorders. J Inherited Metab Dis. 2023;46:874–905.

Article  CAS  PubMed  Google Scholar 

Fernandez-Pereira C, San Millan-Tejado B, Gallardo-Gomez M, Perez-Marquez T, Alves-Villar M, Melcon-Crespo C, et al. Therapeutic approaches in lysosomal storage diseases. Biomolecules. 2021;11. https://doi.org/10.3390/biom11121775

Hannah WB, Derks TGJ, Drumm ML, Grunert SC, Kishnani PS, Vissing J. Glycogen storage diseases. Nat Rev Dis Primers. 2023;9:46.

Article  PubMed  Google Scholar 

Arabi F, Mansouri V, Ahmadbeigi N. Gene therapy clinical trials, where do we go? An overview Biomed Pharmacother. 2022;153: 113324.

Article  CAS  PubMed  Google Scholar 

Maestro S, Weber ND, Zabaleta N, Aldabe R, Gonzalez-Aseguinolaza G. Novel vectors and approaches for gene therapy in liver diseases. JHEP Rep. 2021;3: 100300.

Article  PubMed  PubMed Central  Google Scholar 

Parenti G, Medina DL, Ballabio A. The rapidly evolving view of lysosomal storage diseases. EMBO Mol Med. 2021;13: e12836.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci U S A. 1990;87:1913–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency–macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med. 1991;324:1464–70.

Article  CAS  PubMed  Google Scholar 

U.S. Food and Drug Administration. FDA approves first enzyme replacement therapy for rare alpha-mannosidosis. 2023. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-enzyme-replacement-therapy-rare-alpha-mannosidosis. Accessed 31 Dec 2023.

U.S. Food and Drug Administration. FDA approves first treatment for patients with rare inherited blood clotting disorder. 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-rare-inherited-blood-clotting-disorder. Accessed 31 Dec 2023.

PR Newswire. Chiesi Global Rare Diseases and Protalix BioTherapeutics announce FDA approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the treatment of Fabry Disease. 2023. https://www.prnewswire.com/news-releases/chiesi-global-rare-diseases-and-protalix-biotherapeutics-announce-fda-approval-of-elfabrio-pegunigalsidase-alfa-iwxj-for-the-treatment-of-fabry-disease-301820680.html. Accessed 31 Dec 2023.

European Medicines Agency. Elfabrio. 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/elfabrio. Accessed 31 Dec 2023.

Concolino D, Deodato F, Parini R. Enzyme replacement therapy: efficacy and limitations. Ital J Pediatr. 2018;44:120.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de la Fuente M, Lombardero L, Gomez-Gonzalez A, Solari C, Angulo-Barturen I, Acera A, et al. Enzyme therapy: Current challenges and future perspectives. Int J Mol Sci. 2021;22. https://doi.org/10.3390/ijms22179181.

Silva AKA, Sagné C, Gazeau F, Abasolo I. Enzyme replacement therapy: current challenges and drug delivery prospects via extracellular vesicles. Rare Disease and Orphan Drugs Journal. 2022;1. https://doi.org/10.20517/rdodj.2022.09.

Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, et al. Treatment of Fabry’s Disease with the pharmacologic chaperone Migalastat. N Engl J Med. 2016;375:545–55.

Article  CAS  PubMed  Google Scholar 

Liguori L, Monticelli M, Allocca M, Hay Mele B, Lukas J, Cubellis MV, Andreotti G. Pharmacological chaperones: A therapeutic approach for diseases caused by destabilizing missense mutations. Int J Mol Sci. 2020;21. https://doi.org/10.3390/ijms21020489.

Tran ML, Genisson Y, Ballereau S, Dehoux C. Second-generation pharmacological chaperones: Beyond inhibitors. Molecules. 2020;25. https://doi.org/10.3390/molecules25143145.

Coutinho MF, Santos JI, Alves S. Less is more: Substrate reduction therapy for lysosomal storage disorders. Int J Mol Sci. 2016;17(7):1065. https://doi.org/10.3390/ijms17071065.

Amicus Therapeutics. Amicus Therapeutics announces FDA approval and launch of new treatment for Pompe Disease. 2023. https://ir.amicusrx.com/news-releases/news-release-details/amicus-therapeutics-announces-fda-approval-and-launch-new. Accessed 31 Dec 2023.

European Medicines Agency. Libmeldy. 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/libmeldy. Accessed 31 Dec 2023.

U.S. Food and Drug Administration. FDA approves first gene therapy for children with metachromatic leukodystrophy. 2024.